Schettini, Francesco
De Bonis, Maria Valeria
Strina, Carla
Milani, Manuela
Ziglioli, Nicoletta
Aguggini, Sergio
Ciliberto, Ignazio
Azzini, Carlo
Barbieri, Giuseppina
Cervoni, Valeria
Cappelletti, Maria Rosa
Ferrero, Giuseppina
Ungari, Marco
Locci, Mariavittoria
Paris, Ida
Scambia, Giovanni
Ruocco, Gianpaolo
Generali, Daniele
Funding for this research was provided by:
European Society for Medical Oncology
Fundación BBVA
AstraZeneca
Mednote
Article History
Received: 22 February 2023
Accepted: 14 July 2023
First Online: 24 July 2023
Competing interests
: DG declared personal fees for educational activities from Novartis, Lilly, Pfizer, Roche and Astrazeneca, outside of the submitted work. FS declared personal fees for educational activities from Novartis, outside of the submitted work. IP has declared consulting fees from Roche, Novartis, Lilly, Pfizer, Astra-Zeneca, Pierre Fabre and Ipsen outside of the submitted work. GS has declared Grant/Research Support from MSD Italia S.r.l., consulting role for TESARO Bio Italy S.r.l. Johnson & Johnson and Clovis Oncology Italy S.r.l., outside of the submitted work. All other authors declared no conflict of interest.